Skip to content

Efficacy of Osteopathic Treatment on the Side Effects of Curative Treatments of Lymphoblastic Leukemia in Pediatrics

Efficacy of Osteopathic Treatment on the Side Effects of Curative Treatments of Lymphoblastic Leukemia in Pediatrics

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05664230
Acronym
Leucosteo
Enrollment
15
Registered
2022-12-23
Start date
2023-01-01
Completion date
2023-08-01
Last updated
2022-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoblastic Leukemia

Keywords

osteopathy

Brief summary

During the curative treatment of cancer, pain often remains the dominant symptom affecting the physical and psychological state of the patient. Osteopathy is an exclusively manual practice whose goal is to compensate for mobility dysfunctions of the tissues of the human body. It can be used as a complementary treatment for cancer pain when pain medications are not enough. The aim of this study is to examine the effectiveness of osteopathy in reducing pain intensity and improving quality of life in patients treated for pediatric acute lymphoblastic leukemia.

Detailed description

During the curative treatment of cancer, pain often remains the dominant symptom affecting the physical and psychological state of the patient. Osteopathy is an exclusively manual practice whose goal is to compensate for mobility dysfunctions of the tissues of the human body. It can be used as a complementary treatment for cancer pain when pain medications are not enough. The aim of this study is to examine the effectiveness of osteopathy in reducing pain intensity and improving quality of life in patients treated for pediatric acute lymphoblastic leukemia. Primary objective : To evaluate the effectiveness of five osteopathy sessions at regular intervals on the characteristics of the pain felt in patients aged 1 to 10 years treated for acute lymphoblastic leukemia using the HEDEN scale (Hetero-Evaluation Pain Child).

Interventions

five osteopathy sessions

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 10 Years
Healthy volunteers
No

Inclusion criteria

* Patient managed and treated with a diagnosis of acute lymphoblastic leukemia * Patient between 1 and 10 years of age * Patient with pain at inclusion, or pain at diagnosis related to leukemia * Social security affiliation or entitlement * Signature of informed consent by both parents

Exclusion criteria

* No pain reported at the time of management or diagnosis * Surgery less than 30 days old * Patient with another contraindication to osteopathic treatment (worsening of the condition, bleeding syndrome), or a psychiatric pathology that prevents the scales from being used.

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the effectiveness of 5 weekly osteopathy sessions at regular intervals from week 1 to week 5 on the characteristics of the pain felt in patients aged 1 to 10 years treated for acute lymphoblastic leukemia using the HEDEN scale.5 weeksHEDEN (Hetero-Evaluation Pain Child) score before and after each intervention

Secondary

MeasureTime frameDescription
Evaluate the effectiveness of 5 weekly osteopathy sessions at regular intervals from week 1 to week 5 on the intensity of the pain felt in patients aged 4 to 10 years treated for acute lymphoblastic leukemia using the face scale: FPS -R.5 weeksFPS-R (Face Pain Scale-Revised) score before and after each osteopathy session
To study the variations in quality of life at inclusion and at the end of the study using the PedsQL™ (questionnaire quality of life in paediatrics).5 weeksPedsQL™ Questionnaire quality of life in paediatrics

Countries

France

Contacts

Primary ContactBenoit BRETHON, MD
benoit.brethon@aphp.fr+33171282536
Backup ContactLaurent STUBBE, MD
laurent.stubbe@eso-suposteo.fr+33164614870

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026